Patents by Inventor Thomas W. Chalberg

Thomas W. Chalberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180320145
    Abstract: The present disclosure provides polynucleotide cassettes, expression vectors and methods for the expression of a gene in cone cells.
    Type: Application
    Filed: May 18, 2018
    Publication date: November 8, 2018
    Inventors: Thomas W. Chalberg, JR., Jay Neitz, Maureen Neitz
  • Publication number: 20180311319
    Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
    Type: Application
    Filed: April 24, 2018
    Publication date: November 1, 2018
    Inventors: Ian J. CONSTABLE, P. Elizabeth RAKOCZY, Chooi-May LAI, Thomas W. CHALBERG
  • Patent number: 10004788
    Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: June 26, 2018
    Assignee: Avalanche Australia Pty Ltd.
    Inventors: Ian J. Constable, P. Elizabeth Rakoczy, Chooi-May Lai, Thomas W. Chalberg, Jr.
  • Patent number: 10000741
    Abstract: The present disclosure provides polynucleotide cassettes, expression vectors and methods for the expression of a gene in cone cells.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: June 19, 2018
    Assignees: Adverum Biotechnologies, Inc., University of Washington
    Inventors: Thomas W. Chalberg, Jay Neitz, Maureen Neitz
  • Publication number: 20180125948
    Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
    Type: Application
    Filed: December 21, 2017
    Publication date: May 10, 2018
    Inventors: Ian J. CONSTABLE, P. Elizabeth RAKOCZY, Chooi-May LAI, Thomas W. CHALBERG, Jr.
  • Patent number: 9943573
    Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: April 17, 2018
    Assignee: Avalanche Australia PTY Ltd.
    Inventors: Ian J. Constable, P. Elizabeth Rakoczy, Chooi-May Lai, Thomas W. Chalberg, Jr.
  • Publication number: 20180066022
    Abstract: Methods and compositions are provided for intravitreally delivering a polynucleotide to cone photoreceptors. Aspects of the methods include injecting a recombinant adeno-associated virus comprising a polynucleotide of interest into the vitreous of the eye. These methods and compositions find particular use in treating ocular disorders associated with cone dysfunction and/or death.
    Type: Application
    Filed: March 2, 2016
    Publication date: March 8, 2018
    Inventors: Thomas W. Chalberg, Jay Neitz, Maureen Neitz
  • Publication number: 20170205977
    Abstract: Methods for displaying an e-book using a combination of colors for text and background that have a reduced myopiagenic effect compared to black text on white background, include: presenting a user with one or more combinations of colors for the text and background identified as having a reduced myopiagenic effect, wherein none of the presented combinations comprise either black or white text or either black or white background, and, when viewed by the user's retina, an image composed of text and background rendered in any of the presented color combinations provides reduced center-surround contrast on the user's retina compared to the image viewed as black text on white background; receiving a selection of one of the color combinations from the user; and displaying the e-book file using the combination of colors for the text and background selected by the user.
    Type: Application
    Filed: January 18, 2017
    Publication date: July 20, 2017
    Inventors: Michael Benjamin Selkowe Fertik, Thomas W. Chalberg, JR.
  • Publication number: 20150259395
    Abstract: The present disclosure provides polynucleotide cassettes, expression vectors and methods for the expression of a gene in cone cells.
    Type: Application
    Filed: March 17, 2015
    Publication date: September 17, 2015
    Inventors: Thomas W. Chalberg, Jay Neitz, Maureen Neitz
  • Publication number: 20150004101
    Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
    Type: Application
    Filed: May 19, 2014
    Publication date: January 1, 2015
    Applicant: Avalanche Australia Pty Ltd.
    Inventors: Ian J. Constable, P. Elizabeth Rakoczy, Chooi-May Lai, Thomas W. Chalberg, JR.
  • Publication number: 20140371438
    Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
    Type: Application
    Filed: May 19, 2014
    Publication date: December 18, 2014
    Applicant: Avalanche Australia Pty Ltd.
    Inventors: Ian J. Constable, P. Elizabeth Rakoczy, Chooi-May Lai, Thomas W. Chalberg, JR.
  • Publication number: 20140341977
    Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
    Type: Application
    Filed: May 19, 2014
    Publication date: November 20, 2014
    Applicant: Avalanche Australia Pty Ltd.
    Inventors: Ian J. Constable, Elizabeth P. Rakoczy, Chooi-May Lai, Thomas W. Chalberg, JR.
  • Publication number: 20130323302
    Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
    Type: Application
    Filed: May 7, 2013
    Publication date: December 5, 2013
    Applicants: Lions Eye Institute Limited, Avalanche Australia Pty Ltd.
    Inventors: Ian J. Constable, Elizabeth P. Rakoczy, Chooi-May Lai, Thomas W. Chalberg, JR.
  • Patent number: 8283171
    Abstract: The present invention provides a method and apparatus for transferring an agent into a cell. The method includes the steps of providing an agent outside of a cell and generating a vapor bubble and a plasma discharge between an avalanche electrode and a conductive fluid surrounding the cell. The vapor bubble and plasma discharge generate a mechanical stress wave and an electric field, respectively. The combination of this mechanical stress wave and electric field results in permeabilization of the cell, which in turn results in transfer of the agent into the cell.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: October 9, 2012
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Alexander Vankov, Thomas W. Chalberg, Philip Huie, Jr., Daniel V. Palanker
  • Patent number: 8101169
    Abstract: The present invention provides a method of treating an ocular disease in a subject. In a first step, a nucleic acid is introduced into cells or a tissue. The nucleic acid is introduced by electron avalanche transfection. With this technique, a high electric field induces a vapor bubble and plasma discharge between an electrode and the surrounding medium. The formation of a vapor bubble generates mechanical stress. Plasma discharge through the ionized vapor in the bubble enables connectivity between the electrode and the surrounding medium, so that mechanical stress and electric field are applied simultaneously, which results in permeabilization of the cells or tissue. This permeabilization in turn allows the nucleic acid to enter the cell or tissue. Cells or tissue containing the nucleic acid are then transplanted into an ocular region of the subject.
    Type: Grant
    Filed: August 15, 2006
    Date of Patent: January 24, 2012
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Thomas W. Chalberg, Jr., Mark Blumenkranz, Daniel V. Palanker, Alexander Vankov, Philip Huie, Jr., Michael F. Marmor, Michele P. Calos
  • Publication number: 20110229952
    Abstract: The present invention provides a method and apparatus for transferring an agent into a cell. The method includes the steps of providing an agent outside of a cell and generating a vapor bubble and a plasma discharge between an avalanche electrode and a conductive fluid surrounding the cell. The vapor bubble and plasma discharge generate a mechanical stress wave and an electric field, respectively. The combination of this mechanical stress wave and electric field results in permeabilization of the cell, which in turn results in transfer of the agent into the cell.
    Type: Application
    Filed: March 8, 2011
    Publication date: September 22, 2011
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Alexander Vankov, Thomas W. Chalberg, JR., Philip Huie, JR., Daniel V. Palanker
  • Patent number: 7923251
    Abstract: The present invention provides a method and apparatus for transferring an agent into a cell. The method includes the steps of providing an agent outside of a cell and generating a vapor bubble and a plasma discharge between an avalanche electrode and a conductive fluid surrounding the cell. The vapor bubble and plasma discharge generate a mechanical stress wave and an electric field, respectively. The combination of this mechanical stress wave and electric field results in permeabilization of the cell, which in turn results in transfer of the agent into the cell.
    Type: Grant
    Filed: September 22, 2006
    Date of Patent: April 12, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Alexander Vankov, Thomas W. Chalberg, Jr., Philip Huie, Jr., Daniel V. Palanker
  • Publication number: 20100227408
    Abstract: The present invention provides a method and apparatus for transferring an agent into a cell. The method includes the steps of providing an agent outside of a cell and generating a vapor bubble and a plasma discharge between an avalanche electrode and a conductive fluid surrounding the cell. The vapor bubble and plasma discharge generate a mechanical stress wave and an electric field, respectively. The combination of this mechanical stress wave and electric field results in permeabilization of the cell, which in turn results in transfer of the agent into the cell.
    Type: Application
    Filed: September 22, 2006
    Publication date: September 9, 2010
    Inventors: Alexander Vankov, Thomas W. Chalberg, JR., Philip Huie, JR., Daniel V. Palanker
  • Publication number: 20090203067
    Abstract: Photobioreactors and systems for growth of a photosynthetic organism are provided herein. The systems and photobioreactors can comprise features and modifications in order to improve photosynthetic growth efficiency and light energy utilization. Also provided are methods and systems to improve the cost-effectiveness of a photobioreactor system for growth of a photosynthetic organism.
    Type: Application
    Filed: September 18, 2008
    Publication date: August 13, 2009
    Inventors: Matthew W. Eckerle, Thomas W. Chalberg, JR., Cheryl A. Hackworth, Michael B. Fertik
  • Publication number: 20090148928
    Abstract: Methods and systems of cultivating photosynthetic cells under autotrophic and heterotrophic growth conditions are described herein. Under different growing conditions, photosynthetic cells may produce different quantities and characteristics of lipids. The methods and systems herein utilize changing growth conditions to alter the macromolecular content of a photosynthetic cell.
    Type: Application
    Filed: November 26, 2008
    Publication date: June 11, 2009
    Inventors: Cheryl A. Hackworth, Thomas W. Chalberg, JR.